App aims to boost breast cancer treatment adherence in real-world study
NCT ID NCT06905301
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether using a mobile app helps people with HR+ HER2- stage II or III breast cancer stick to their prescribed ribociclib and aromatase inhibitor therapy for a full year. The app provides reminders and information about side effects and relapse risks. About 240 participants will be split into two groups—one using the app and one not—to compare how many stay on treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGPskov, Russia, 180000, Russia
-
Novartis Investigative Site
RECRUITINGMoscow, 115304, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 194017, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 194291, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 197758, Russia
-
Novartis Investigative Site
RECRUITINGSestroretsk, 197706, Russia
-
Novartis Investigative Site
RECRUITINGUfa, 450054, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?